Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Rating of “Moderate Buy” by Analysts

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has received an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $18.00.

Several analysts have commented on the stock. BTIG Research lowered their target price on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Raymond James Financial raised Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Wednesday, July 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th. Piper Sandler raised Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a research report on Wednesday, July 8th. Finally, UBS Group raised Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research report on Wednesday, July 8th.

Institutional Trading of Tvardi Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TVRD. Vanguard Group Inc. increased its stake in shares of Tvardi Therapeutics by 5.2% during the 3rd quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock valued at $16,335,000 after acquiring an additional 20,757 shares during the last quarter. American Financial Group Inc. acquired a new stake in shares of Tvardi Therapeutics in the fourth quarter worth approximately $962,000. Vestal Point Capital LP acquired a new stake in shares of Tvardi Therapeutics in the third quarter worth approximately $6,508,000. Geode Capital Management LLC grew its holdings in Tvardi Therapeutics by 6.2% in the fourth quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock valued at $676,000 after purchasing an additional 9,214 shares during the period. Finally, State Street Corp grew its holdings in Tvardi Therapeutics by 83.7% in the fourth quarter. State Street Corp now owns 115,501 shares of the company’s stock valued at $497,000 after purchasing an additional 52,637 shares during the period. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Price Performance

Tvardi Therapeutics stock opened at $1.82 on Monday. The stock has a market capitalization of $24.28 million, a P/E ratio of -0.65 and a beta of 0.39. Tvardi Therapeutics has a 12-month low of $1.50 and a 12-month high of $43.65. The firm’s 50-day moving average is $2.32 and its two-hundred day moving average is $3.03.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). As a group, analysts forecast that Tvardi Therapeutics will post -2.35 EPS for the current year.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.